Current Report Filing (8-k)
September 08 2016 - 8:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8K
CURRENT REPORT
Pursuant
to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2016
Recro Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Pennsylvania
|
|
001-36329
|
|
26-1523233
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
490 Lapp Road,
Malvern, Pennsylvania
|
|
19355
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (484) 395-2470
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
|
¨
|
Precommencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
|
¨
|
Precommencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))
|
Item 7.01 Regulation FD Disclosure.
On September 7, 2016, Recro Pharma, Inc. (the Company) announced that it will present a poster presentation entitled An Evaluation of
the Safety and Efficacy of N1539, a Novel Intravenous Formulation of NanoCrystalMeloxicam, Administered By IV Push in Subjects with Moderate to Severe Pain Following Bunionectomy at the this years PAINWeek
®
, the National Conference on Pain for Frontline Practitioners, taking place in Las Vegas, NV from September 6 10, 2016.
The information disclosed under Item 7.01 is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On September 7, 2016, the Company issued a press release announcing the poster presentations at the
PAINWeek
®
conference. A copy of the press release is filed herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Document
|
|
|
99.1
|
|
Press release of Recro Pharma, Inc., dated September 7, 2016.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: September 8, 2016
|
|
|
Recro Pharma, Inc.
|
|
|
By:
|
|
/s/ Gerri A. Henwood
|
|
|
Name: Gerri A. Henwood
|
|
|
Title: Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Document
|
|
|
99.1
|
|
Press release of Recro Pharma, Inc., dated September 7, 2016.
|
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Sep 2023 to Sep 2024